Business Context and Reporting Period
This Form 8-K filing by Spruce Biosciences, Inc. (SPRB) was submitted on October 24, 2024. The report addresses a regulatory notice regarding the continued listing of the Company's common stock on the Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on listing compliance status rather than financial performance metrics.
Material Changes
- Listing Transfer: Effective October 28, 2024, the Company's common stock will be transferred from the Nasdaq Global Select Market to the Nasdaq Capital Market.
- Compliance Extension: Nasdaq granted an additional 180 calendar days (until April 21, 2025) to regain compliance with the minimum closing bid price requirement (Rule 5550(a)(2)).
- Deficiency: The Company currently fails to meet the $1.00 minimum closing bid price requirement.
Outlook, Risks, and Management Commentary
Management intends to actively monitor the bid price and consider available options to resolve the deficiency, including effecting a reverse stock split if necessary. To achieve compliance, the closing bid price must reach at least $1.00 per share for a minimum of 10 consecutive business days before April 21, 2025.
Risks: There is no assurance that the Company will regain compliance. Failure to do so within the extended period will result in a notice of delisting. The Company retains the right to appeal a delisting determination to a Nasdaq Hearings Panel.
Investor Verification Checklist
- Verify the current trading status and market tier (Nasdaq Capital Market) of SPRB shares.
- Monitor the daily closing bid price to track progress toward the $1.00 threshold.
- Watch for future announcements regarding a potential reverse stock split.
- Review the April 21, 2025 deadline for final compliance determination.